This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BRX-345, OR-04
Description: Arimoclomol provides cellular protection from abnormal proteins by activating molecular chaperone proteins that can repair or degrade the damaged proteins that are believed to cause many diseases, including ALS.
Deal Structure: In October 2004, for a cash purchase price of $3,000,000, CytRx acquired all the clinical and pharmaceutical assets and related intellectual property of Hungary-based privately held Biorex Research & Development RT, including the acquisition of arimoclomol.
In May 2011, CytRx announced that it has sold the worldwide rights to its molecular chaperone assets to Orphazyme ApS.
Pink Sheet CytRx arimoclomol clinical hold
Pink Sheet CytRx arimoclomol begins Phase II
Additional information available to subscribers only: